<?xml version="1.0" encoding="UTF-8"?>
<search_results count="1046">
  <query>SEARCH[STUDY] ( Crohn's Disease [STUDY:ALL-FIELDS] )</query>
  <clinical_study>
    <order>601</order>
    <score>0.78577</score>
    <nct_id>NCT02674308</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02674308</url>
    <title>Entyvio (Vedolizumab) Long Term Safety Study</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Ulcerative Colitis and Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab; Other: Other Biologic Agents</intervention_summary>
    <last_changed>June 1, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>602</order>
    <score>0.78224</score>
    <nct_id>NCT02760615</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02760615</url>
    <title>Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Colitis, Ulcerative; Crohn Disease</condition_summary>
    <intervention_summary>Drug: Caffeine; Drug: Losartan; Drug: Omeprazole; Drug: Dextromethorphan; Drug: Midazolam; Drug: Vedolizumab</intervention_summary>
    <last_changed>June 23, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>603</order>
    <score>0.78189</score>
    <nct_id>NCT03096379</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03096379</url>
    <title>MRI Differentiating Gut TB and Crohn's</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease; Intestinal Tuberculosis</condition_summary>
    <intervention_summary>Diagnostic Test: Magnetic resonance imaging</intervention_summary>
    <last_changed>March 24, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>604</order>
    <score>0.78163</score>
    <nct_id>NCT02620046</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02620046</url>
    <title>Vedolizumab Subcutaneous Long-Term Open-Label Extension Study</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Colitis, Ulcerative; Crohn Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab SC</intervention_summary>
    <last_changed>June 22, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>605</order>
    <score>0.78069</score>
    <nct_id>NCT00707512</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00707512</url>
    <title>CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: natalizumab</intervention_summary>
    <last_changed>July 16, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>606</order>
    <score>0.77154</score>
    <nct_id>NCT01804166</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01804166</url>
    <title>A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Hepatosplenic T-Cell Lymphoma</condition_summary>
    <intervention_summary>Biological: Collection of samples</intervention_summary>
    <last_changed>January 23, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>607</order>
    <score>0.77018</score>
    <nct_id>NCT02986724</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02986724</url>
    <title>A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants Wtih Ulcerative Colitis (UC) or Crohn´s Disease (CD)</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease; Colitis, Ulcerative; Inflammatory Bowel Diseases</condition_summary>
    <last_changed>January 19, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>608</order>
    <score>0.76732</score>
    <nct_id>NCT01468090</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01468090</url>
    <title>Disease Course in an IBD Cohort in the Era of Biological Treatment</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <last_changed>September 15, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>609</order>
    <score>0.7635</score>
    <nct_id>NCT00798473</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00798473</url>
    <title>Zoledronate for Osteopenia in Pediatric Crohn's</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Osteopenia; Osteoporosis</condition_summary>
    <intervention_summary>Drug: zoledronic acid; Other: IV saline infusion</intervention_summary>
    <last_changed>November 25, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>610</order>
    <score>0.76039</score>
    <nct_id>NCT03010787</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03010787</url>
    <title>A First Time in Human Study in Healthy Volunteers and Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: V565; Drug: V565; Drug: Placebo; Drug: V565; Drug: V565</intervention_summary>
    <last_changed>January 4, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>611</order>
    <score>0.75833</score>
    <nct_id>NCT03134586</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03134586</url>
    <title>Advanced Non-Invasive Diagnostics in Inflammatory Bowel Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Other: Diagnostic imaging</intervention_summary>
    <last_changed>April 25, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>612</order>
    <score>0.75821</score>
    <nct_id>NCT02412553</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02412553</url>
    <title>Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Specific carbohydrate diet; Other: Elemental diet</intervention_summary>
    <last_changed>March 21, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>613</order>
    <score>0.75663</score>
    <nct_id>NCT01012570</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01012570</url>
    <title>The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Application of Adalimumab</intervention_summary>
    <last_changed>December 3, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>614</order>
    <score>0.75596</score>
    <nct_id>NCT00724529</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00724529</url>
    <title>Post Marketing Surveillance of Remicade</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Ankylosing Spondylitis</condition_summary>
    <intervention_summary>Biological: Infliximab</intervention_summary>
    <last_changed>January 21, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>615</order>
    <score>0.7542</score>
    <nct_id>NCT01847170</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01847170</url>
    <title>Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients With Moderate to Severe Inflammatory Bowel Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Fecal Microbial Transplantation</intervention_summary>
    <last_changed>March 2, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>616</order>
    <score>0.75403</score>
    <nct_id>NCT00752622</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00752622</url>
    <title>Treatment With Infliximab in a Medical Setting (Study P05587)</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Infliximab 5 mg/kg; Biological: Infliximab 5 mg/kg every 6 weeks; Biological: Infliximab 7 mg/kg every 8 weeks</intervention_summary>
    <last_changed>March 16, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>617</order>
    <score>0.75343</score>
    <nct_id>NCT02054533</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02054533</url>
    <title>Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <last_changed>January 3, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>618</order>
    <score>0.75072</score>
    <nct_id>NCT01316601</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01316601</url>
    <title>A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: QAX567</intervention_summary>
    <last_changed>May 27, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>619</order>
    <score>0.75064</score>
    <nct_id>NCT01293656</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01293656</url>
    <title>Study of Participants With Crohn's Disease and Ulcerative Colitis in Eastern Europe, Middle East, and North Africa (P08166)</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis</condition_summary>
    <intervention_summary>Other: No intervention.</intervention_summary>
    <last_changed>June 1, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>620</order>
    <score>0.75035</score>
    <nct_id>NCT03220243</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03220243</url>
    <title>Stem Cell Coated Fistula Plug in Patients With Crohn's RVF</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Fistula Vagina; Crohn Disease</condition_summary>
    <intervention_summary>Drug: MSC-AFP</intervention_summary>
    <last_changed>July 17, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>621</order>
    <score>0.74963</score>
    <nct_id>NCT02704624</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02704624</url>
    <title>Effects of Supplementation of Vitamin D in Patients With Crohn`s Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease; Vitamin D Deficiency; Fatigue; Sarcopenia; Muscle Weakness; Disorder of Bone Density and Structure, Unspecified</condition_summary>
    <intervention_summary>Dietary Supplement: Vitamin D; Other: Placebo</intervention_summary>
    <last_changed>December 1, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>622</order>
    <score>0.7446</score>
    <nct_id>NCT02108821</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02108821</url>
    <title>Fecal Microbiota Transplantation in Pediatric Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammatory Bowel Diseases (IBD); Crohn's Disease (CD); Ulcerative Colitis (UC)</condition_summary>
    <intervention_summary>Biological: Fecal Microbiota Transplantation (FMT)</intervention_summary>
    <last_changed>July 18, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>623</order>
    <score>0.74374</score>
    <nct_id>NCT01388257</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01388257</url>
    <title>Anal Crohn Fistula Surgery</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn Disease; Fistula; Anoperineal Fistula; Anal Fistula</condition_summary>
    <intervention_summary>Procedure: All types of surgery procedures; Procedure: Simple seton drain removal</intervention_summary>
    <last_changed>June 6, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>624</order>
    <score>0.74368</score>
    <nct_id>NCT00001184</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00001184</url>
    <title>Immune Regulation in Ulcerative Colitis or Crohn s Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Inflammatory Bowel Disease</condition_summary>
    <last_changed>July 13, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>625</order>
    <score>0.74243</score>
    <nct_id>NCT01876264</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01876264</url>
    <title>Crohn's Extent of Resection Trial</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Recurrence</condition_summary>
    <intervention_summary>Procedure: Extended resection; Procedure: Conventional resection</intervention_summary>
    <last_changed>April 5, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>626</order>
    <score>0.73655</score>
    <nct_id>NCT02395354</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02395354</url>
    <title>PROTDILAT (PROtesis DILATation)</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Stenosis; Crohn's Disease; Chronic Inflammation</condition_summary>
    <intervention_summary>Device: Placing a self-expanding metallic stent; Device: A balloon dilatation</intervention_summary>
    <last_changed>April 13, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>627</order>
    <score>0.73373</score>
    <nct_id>NCT00742781</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00742781</url>
    <title>Vitamin D Supplementation in Crohn's Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Vitamin D</intervention_summary>
    <last_changed>July 8, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>628</order>
    <score>0.73132</score>
    <nct_id>NCT02709694</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02709694</url>
    <title>Imaging Biomarkers in Crohn's Associated Spondyloarthritis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Spondyloarthritis</condition_summary>
    <intervention_summary>Other: No intervention</intervention_summary>
    <last_changed>June 29, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>629</order>
    <score>0.72626</score>
    <nct_id>NCT03142321</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03142321</url>
    <title>Defining Predictors of RT Response to Vedolizumab in IBD</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease of Small Intestine</condition_summary>
    <intervention_summary>Drug: Vedolizumab 300 MG Injection [Entyvio]</intervention_summary>
    <last_changed>May 3, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>630</order>
    <score>0.72592</score>
    <nct_id>NCT00152841</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00152841</url>
    <title>Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis; Mild or Moderate Anaemia</condition_summary>
    <intervention_summary>Drug: Iron supplement 300-600 mg/day; Drug: Vitamin E 800IU</intervention_summary>
    <last_changed>March 16, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>631</order>
    <score>0.71867</score>
    <nct_id>NCT02887287</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02887287</url>
    <title>Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease With Complications or Failure of Medical Treatment</condition_summary>
    <intervention_summary>Drug: EEN</intervention_summary>
    <last_changed>September 1, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>632</order>
    <score>0.71654</score>
    <nct_id>NCT01417715</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01417715</url>
    <title>Endomicroscopy for Assessment of Mucosal Healing</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn´s Disease; Ulcerative Colitis</condition_summary>
    <intervention_summary>Device: Endomicroscopy</intervention_summary>
    <last_changed>January 23, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>633</order>
    <score>0.71345</score>
    <nct_id>NCT03161886</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03161886</url>
    <title>24-Week Mucosal Healing and Deep Remission Assessment of Pediatric Crohn's Disease by Colon Capsule Endoscopy</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammatory Bowel Diseases; Children, Only</condition_summary>
    <intervention_summary>Device: Colon Capsule Endoscopy</intervention_summary>
    <last_changed>May 19, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>634</order>
    <score>0.71309</score>
    <nct_id>NCT02622139</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02622139</url>
    <title>Multispectral Optoacoustic Tomography (MSOT) for the Evaluation of Disease Activity in Inflammatory Bowel Diseases (IBD)</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis; IBD</condition_summary>
    <intervention_summary>Device: Multispectral Optoacoustic Tomography (MSOT)</intervention_summary>
    <last_changed>January 11, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>635</order>
    <score>0.71291</score>
    <nct_id>NCT02942511</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02942511</url>
    <title>Predictors Favoring the Role of Exclusive Enteral Nutrition in Active Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Enteral Nutrition</condition_summary>
    <last_changed>October 21, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>636</order>
    <score>0.70473</score>
    <nct_id>NCT01078935</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01078935</url>
    <title>The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <intervention_summary>Dietary Supplement: probiotics; Dietary Supplement: placebo</intervention_summary>
    <last_changed>August 10, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>637</order>
    <score>0.70196</score>
    <nct_id>NCT02847884</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02847884</url>
    <title>IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Inflammatory Bowel Disease; Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Infliximab</intervention_summary>
    <last_changed>July 27, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>638</order>
    <score>0.69956</score>
    <nct_id>NCT02542904</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02542904</url>
    <title>Extensive Mesenteric Excision (EME) Versus Local Mesenteric Excision (LME) for Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Postoperative Disease Recurrence; Crohns Disease</condition_summary>
    <intervention_summary>Procedure: mesenteric excision</intervention_summary>
    <last_changed>January 7, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>639</order>
    <score>0.69792</score>
    <nct_id>NCT00917514</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00917514</url>
    <title>An Investigational Study to Test Usability of the Electronic Dosing Equipment Medicpen</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <last_changed>February 25, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>640</order>
    <score>0.69212</score>
    <nct_id>NCT01757964</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01757964</url>
    <title>Bacteriotherapy in Pediatric Inflammatory Bowel Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis; CD</condition_summary>
    <intervention_summary>Biological: Bacteriotherapy</intervention_summary>
    <last_changed>April 25, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>641</order>
    <score>0.6897</score>
    <nct_id>NCT01787786</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01787786</url>
    <title>Improving Treatment of Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug and Antibody Levels</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <last_changed>December 1, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>642</order>
    <score>0.68854</score>
    <nct_id>NCT02330211</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02330211</url>
    <title>Fecal Microbiota Transplant (FMT) in Pediatric Active Crohn's Colitis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Inflammatory Bowel Diseases; Crohn Disease</condition_summary>
    <intervention_summary>Biological: Fecal Microbiota Transplant; Biological: Placebo</intervention_summary>
    <last_changed>June 16, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>643</order>
    <score>0.68759</score>
    <nct_id>NCT00801125</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00801125</url>
    <title>Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: natalizumab</intervention_summary>
    <last_changed>June 14, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>644</order>
    <score>0.67696</score>
    <nct_id>NCT01266629</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01266629</url>
    <title>The Clinical Utility of Fecal Caprotectin and Lactoferrin in Patients Undergoing Capsular Endoscopy</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>January 10, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>645</order>
    <score>0.67654</score>
    <nct_id>NCT01405105</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01405105</url>
    <title>Exacerbating Factors in Inflammatory Bowel Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <last_changed>February 13, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>646</order>
    <score>0.67588</score>
    <nct_id>NCT02820493</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02820493</url>
    <title>Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: vedolizumab</intervention_summary>
    <last_changed>June 28, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>647</order>
    <score>0.67013</score>
    <nct_id>NCT02869880</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02869880</url>
    <title>Trial of Enhanced Pre-Consent Discussion</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Pediatric Crohn's Disease</condition_summary>
    <intervention_summary>Other: Enhanced Pre-Consent Discussion; Other: Standard Pre-consent Discussion</intervention_summary>
    <last_changed>August 12, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>648</order>
    <score>0.67002</score>
    <nct_id>NCT01417702</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01417702</url>
    <title>Endoscopy for Assessment of Mucosal Healing in IBD</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn´s Disease; Ulcerative Colitis</condition_summary>
    <intervention_summary>Device: High-definition white light endoscopy and i-Scan</intervention_summary>
    <last_changed>January 23, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>649</order>
    <score>0.66917</score>
    <nct_id>NCT01827631</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01827631</url>
    <title>Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: GSK1605786 capsule</intervention_summary>
    <last_changed>June 5, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>650</order>
    <score>0.66881</score>
    <nct_id>NCT00711945</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00711945</url>
    <title>Growth Relapse and Outcomes With Therapy 1</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease; Pediatric Onset</condition_summary>
    <last_changed>July 8, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>651</order>
    <score>0.66868</score>
    <nct_id>NCT01473927</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01473927</url>
    <title>Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Other: Endoscopy; Other: Endoscopy</intervention_summary>
    <last_changed>March 11, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>652</order>
    <score>0.66565</score>
    <nct_id>NCT00955123</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00955123</url>
    <title>Effects of Prednisolone and Infliximab on the Regulation of Urea Synthesis in Active Inflammatory Bowel Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammatory Bowel Diseases</condition_summary>
    <last_changed>October 11, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>653</order>
    <score>0.66319</score>
    <nct_id>NCT02020382</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02020382</url>
    <title>Evaluation of the Diagnostic Value of microRNAs for Inflammatory Bowel Diseases</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Ulcerative Colitis; Crohn Disease; Healthy; Non-IBD Colitis</condition_summary>
    <intervention_summary>Device: qPCR diagnostic KIT of microRNAS</intervention_summary>
    <last_changed>May 31, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>654</order>
    <score>0.65819</score>
    <nct_id>NCT02179372</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02179372</url>
    <title>Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases</title>
    <status open="N">Completed</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Eicosapentaenoic acid; Dietary Supplement: Medium chain fatty acid (placebo)</intervention_summary>
    <last_changed>November 28, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>655</order>
    <score>0.65716</score>
    <nct_id>NCT03003351</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03003351</url>
    <title>Zurich Fistula Cohort Study</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Fistula;Rectal; Fistula; Rectouterine; Fistula; Rectovesical; Fistulas Recto Vaginal; Crohn Disease</condition_summary>
    <last_changed>December 21, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>656</order>
    <score>0.65536</score>
    <nct_id>NCT02883452</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02883452</url>
    <title>A Phase I Study to Evaluate PK, Efficacy and Safety of CT-P13 SC in Patients With Active CD and UC</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <intervention_summary>Biological: Infliximab</intervention_summary>
    <last_changed>May 9, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>657</order>
    <score>0.63788</score>
    <nct_id>NCT01793831</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01793831</url>
    <title>Standardized Fecal Microbiota Transplantation for Crohn&amp;Apos;s Diseases</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Diseases; Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Procedure: FMT; Drug: 5-ASA, Prednisone, Azathioprine or Remicade</intervention_summary>
    <last_changed>November 21, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>658</order>
    <score>0.63405</score>
    <nct_id>NCT00723905</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00723905</url>
    <title>Remicade Infusion Management Program</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease; Arthritis, Rheumatoid</condition_summary>
    <last_changed>January 14, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>659</order>
    <score>0.6314</score>
    <nct_id>NCT02575040</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02575040</url>
    <title>Efficacy of Fecal Microbiota Transplantation for Inflammatory Bowel Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Ulcerative Colitis; Crohn Disease; Constipation (Excl Faecal Impaction)</condition_summary>
    <intervention_summary>Biological: Fecal microbiota transplantation</intervention_summary>
    <last_changed>October 12, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>660</order>
    <score>0.62899</score>
    <nct_id>NCT00820365</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00820365</url>
    <title>SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammatory Bowel Disease (IBD)</condition_summary>
    <intervention_summary>Drug: SC12267 (4SC-101)</intervention_summary>
    <last_changed>May 17, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>661</order>
    <score>0.62562</score>
    <nct_id>NCT00591669</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00591669</url>
    <title>Non-invasive Imaging of GI Inflammation Using Microbubble Contrast Enhanced Ultrasonography</title>
    <status open="N">Terminated</status>
    <condition_summary>Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Other: Definity; Other: Definity</intervention_summary>
    <last_changed>April 25, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>662</order>
    <score>0.62375</score>
    <nct_id>NCT02319798</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02319798</url>
    <title>Telephone Consultation as a Substitute for Routine Out-patient Face-to-face Consultation for Children With Inflammatory Bowel Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <intervention_summary>Other: telephone consultations; Other: face-to-face consultations</intervention_summary>
    <last_changed>December 15, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>663</order>
    <score>0.62306</score>
    <nct_id>NCT02148640</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02148640</url>
    <title>The NOR-SWITCH Study</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Rheumatoid Arthritis; Spondyloarthritis; Psoriatic Arthritis; Ulcerative Colitis; Crohn's Disease; Psoriasis Chronic</condition_summary>
    <intervention_summary>Drug: Innovator infliximab; Drug: Biosimilar infliximab</intervention_summary>
    <last_changed>August 6, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>664</order>
    <score>0.62304</score>
    <nct_id>NCT02293811</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02293811</url>
    <title>Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn Disease-Associated Colorectal Adenocarcinoma</condition_summary>
    <intervention_summary>Other: Analysis</intervention_summary>
    <last_changed>November 14, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>665</order>
    <score>0.61815</score>
    <nct_id>NCT03239704</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03239704</url>
    <title>Improving Outcomes Among Urgent Care Clinic Patients With Inflammatory Bowel Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Inflammatory Bowel Disease; Ulcerative Colitis; Crohn Disease</condition_summary>
    <intervention_summary>Behavioral: Telemedicine Follow-Up; Other: Telemedicine Monitoring; Behavioral: 30 Day Comprehensive Questionnaire</intervention_summary>
    <last_changed>August 2, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>666</order>
    <score>0.61697</score>
    <nct_id>NCT03222011</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03222011</url>
    <title>Stricture Definition and Treatment (STRIDENT) Endoscopic Therapy Study</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease; Inflammatory Bowel Diseases; Stricture; Bowel</condition_summary>
    <intervention_summary>Procedure: Standard (single) endoscopic stricture dilatation; Procedure: Intensive endoscopic stricture dilatation</intervention_summary>
    <last_changed>July 18, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>667</order>
    <score>0.61697</score>
    <nct_id>NCT03220841</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03220841</url>
    <title>Stricture Definition and Treatment (STRIDENT) Drug Therapy Study</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease; Inflammatory Bowel Diseases; Stricture; Bowel</condition_summary>
    <intervention_summary>Drug: Adalimumab Injection; Drug: Thiopurine</intervention_summary>
    <last_changed>July 13, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>668</order>
    <score>0.61625</score>
    <nct_id>NCT01345318</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01345318</url>
    <title>B0151005 Open-Label Extension Study</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: PF-04236921; Biological: PF-04236921</intervention_summary>
    <last_changed>January 30, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>669</order>
    <score>0.61471</score>
    <nct_id>NCT01960426</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01960426</url>
    <title>Evaluation of Health Costs and Resource Utilization</title>
    <status open="N">Terminated</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <intervention_summary>Other: Measurement of drug (Adalimumab/Infliximab); Other: Intensify treatment with the existing drug</intervention_summary>
    <last_changed>May 12, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>670</order>
    <score>0.61406</score>
    <nct_id>NCT02451839</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02451839</url>
    <title>An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease; Rheumatoid Arthritis; Psoriasis</condition_summary>
    <last_changed>July 6, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>671</order>
    <score>0.61337</score>
    <nct_id>NCT02678052</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02678052</url>
    <title>OTIS Vedolizumab Pregnancy Exposure Registry</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Colitis, Ulcerative; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab; Biological: Other Biological Agent</intervention_summary>
    <last_changed>June 6, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>672</order>
    <score>0.61292</score>
    <nct_id>NCT01140789</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01140789</url>
    <title>Chinese Patients With Inflammatory Bowel Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <last_changed>April 23, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>673</order>
    <score>0.61217</score>
    <nct_id>NCT02846961</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02846961</url>
    <title>Anti CT-P13 Antibody in Moderate to Severe Inflammatory Bowel Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Inflammatory Bowel Disease; Ulcerative Colitis; Crohn's Disease</condition_summary>
    <last_changed>August 8, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>674</order>
    <score>0.60797</score>
    <nct_id>NCT00720538</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00720538</url>
    <title>Thalidomide in Pediatric Inflammatory Bowel Diseases.</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammatory Bowel Diseases; Crohn's Disease; Ulcerative Colitis</condition_summary>
    <intervention_summary>Drug: Thalidomide; Drug: placebo</intervention_summary>
    <last_changed>October 25, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>675</order>
    <score>0.60208</score>
    <nct_id>NCT02694042</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02694042</url>
    <title>Mission is Remission®: How Can a Disease Self-management Website Change Care?</title>
    <status open="N">Enrolling by invitation</status>
    <condition_summary>Pediatric Crohn's Disease; Pediatric Ulcerative Colitis</condition_summary>
    <intervention_summary>Behavioral: Mission is Remission®</intervention_summary>
    <last_changed>September 1, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>676</order>
    <score>0.59743</score>
    <nct_id>NCT01720368</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01720368</url>
    <title>OPERA Database - Crohn's Protocol</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammatory Bowel Disease; Crohn's Disease</condition_summary>
    <last_changed>August 14, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>677</order>
    <score>0.59649</score>
    <nct_id>NCT00950105</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00950105</url>
    <title>Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: CPSI-2364 or placebo</intervention_summary>
    <last_changed>August 22, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>678</order>
    <score>0.59543</score>
    <nct_id>NCT00897312</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00897312</url>
    <title>Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Melanoma</condition_summary>
    <intervention_summary>Biological: infliximab; Biological: pegylated interferon alfa; Biological: ticilimumab; Drug: ribavirin; Other: high performance liquid chromatography; Other: laboratory biomarker analysis</intervention_summary>
    <last_changed>April 21, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>679</order>
    <score>0.59454</score>
    <nct_id>NCT01524120</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01524120</url>
    <title>Endoscopy and Endomicroscopy for Assessment of Mucosal Healing in Inflammatory Bowel Disease (IBD)</title>
    <status open="N">Unknown status</status>
    <condition_summary>Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis</condition_summary>
    <intervention_summary>Device: Endoscopy (EPK-i, Pentax, Tokyo, Japan); Device: Endomicroscopy (iCLE, Pentax, Tokyo, Japan); Device: Endoscopy (EPK-i, Pentax, Tokyo, Japan); Device: Endomicroscopy (iCLE, Pentax, Tokyo, Japan)</intervention_summary>
    <last_changed>January 23, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>680</order>
    <score>0.58849</score>
    <nct_id>NCT02130349</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02130349</url>
    <title>IBDSL Biobank Project. Molecular Markers for Diagnosis and Therapy Response in IBD.</title>
    <status open="Y">Recruiting</status>
    <condition_summary>IBD; Crohns Disease; Ulcerative Colitis</condition_summary>
    <last_changed>March 15, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>681</order>
    <score>0.5877</score>
    <nct_id>NCT03090139</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03090139</url>
    <title>Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Colitis, Ulcerative; Crohn Disease; Inflammatory Bowel Diseases</condition_summary>
    <intervention_summary>Drug: Anti-TNF Therapy</intervention_summary>
    <last_changed>April 19, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>682</order>
    <score>0.58754</score>
    <nct_id>NCT02452151</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02452151</url>
    <title>&quot;Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial&quot;</title>
    <status open="N">Unknown status</status>
    <condition_summary>Colitis, Ulcerative; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Infliximab-Biosimilar; Drug: Infliximab-Innovator</intervention_summary>
    <last_changed>May 21, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>683</order>
    <score>0.58726</score>
    <nct_id>NCT01974869</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01974869</url>
    <title>Anti Tumor Necrosis Factor Alpha Agents and Surgical Stress Response</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammatory Bowel Diseases</condition_summary>
    <intervention_summary>Drug: Anti-tumor necrosis factor alpha agents</intervention_summary>
    <last_changed>February 6, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>684</order>
    <score>0.58709</score>
    <nct_id>NCT02087878</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02087878</url>
    <title>A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis; Hepatosplenic T-Cell Lymphoma</condition_summary>
    <last_changed>August 1, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>685</order>
    <score>0.58573</score>
    <nct_id>NCT02612103</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02612103</url>
    <title>Biomarkers in Inflammatory Bowel Diseases</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Inflammatory Bowel Disease; Colitis, Ulcerative; Crohn Disease</condition_summary>
    <last_changed>October 11, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>686</order>
    <score>0.58505</score>
    <nct_id>NCT02508012</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02508012</url>
    <title>Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <intervention_summary>Other: Immuno monitoring</intervention_summary>
    <last_changed>July 23, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>687</order>
    <score>0.58197</score>
    <nct_id>NCT00114803</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00114803</url>
    <title>Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Calcitonin nasal spray (salmon)</intervention_summary>
    <last_changed>December 4, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>688</order>
    <score>0.57812</score>
    <nct_id>NCT00289328</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00289328</url>
    <title>Glucocorticoid-induced Osteopenia in Children</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Nephrotic Syndrome</condition_summary>
    <last_changed>March 1, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>689</order>
    <score>0.57734</score>
    <nct_id>NCT00475410</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00475410</url>
    <title>Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Anal Fistula</condition_summary>
    <intervention_summary>Drug: ASCs (Cx401, company code); Drug: Fibrin adhesive</intervention_summary>
    <last_changed>June 13, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>690</order>
    <score>0.57614</score>
    <nct_id>NCT01813500</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01813500</url>
    <title>Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis; Clostridium Difficile; Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Other: Blood and stool sample</intervention_summary>
    <last_changed>April 25, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>691</order>
    <score>0.57293</score>
    <nct_id>NCT02953275</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02953275</url>
    <title>Synergistic Effect of Vedolizumab and Pentoxifylline</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: vedolizumab; Drug: Pentoxifylline; Drug: placebo</intervention_summary>
    <last_changed>May 12, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>692</order>
    <score>0.56948</score>
    <nct_id>NCT00516776</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00516776</url>
    <title>The Innate Immune System and Inflammatory Bowel Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <last_changed>August 16, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>693</order>
    <score>0.56914</score>
    <nct_id>NCT02801240</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02801240</url>
    <title>Effect of a Comprehensive Nutrition Support Product on the Nutritional Status of Adults With Inflammatory Bowel Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Colitis, Ulcerative; Crohn's Disease</condition_summary>
    <intervention_summary>Other: Nutrition support product</intervention_summary>
    <last_changed>February 23, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>694</order>
    <score>0.56849</score>
    <nct_id>NCT02745457</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02745457</url>
    <title>Body Composition in Children With Inflammatory Bowel Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <last_changed>December 6, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>695</order>
    <score>0.56795</score>
    <nct_id>NCT02998827</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02998827</url>
    <title>Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients</title>
    <status open="N">Enrolling by invitation</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Thalidomide; Drug: infliximab, azathioprine; Other: enteral nutrition</intervention_summary>
    <last_changed>December 19, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>696</order>
    <score>0.56725</score>
    <nct_id>NCT01364896</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01364896</url>
    <title>Anal Human Papillomavirus in Inflammatory Bowel Disease Study</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammatory Bowel Disease (IBD); Ulcerative Colitis (UC); Crohn's Disease (CD); Anal Human Papillomavirus</condition_summary>
    <intervention_summary>Procedure: Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples</intervention_summary>
    <last_changed>March 9, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>697</order>
    <score>0.56638</score>
    <nct_id>NCT03027193</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03027193</url>
    <title>A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccine ChAdOx2 HAV in Healthy Adult Volunteers</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Biological: ChAdOx2 HAV</intervention_summary>
    <last_changed>February 13, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>698</order>
    <score>0.56631</score>
    <nct_id>NCT01611805</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01611805</url>
    <title>Japanese Phase I of GSK1605786</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: GSK1605786; Drug: GSK1605786 Placebo</intervention_summary>
    <last_changed>June 13, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>699</order>
    <score>0.56574</score>
    <nct_id>NCT02770599</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02770599</url>
    <title>Improving the Health Care in Inflammatory Bowel Disease.</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease; Colitis, Ulcerative</condition_summary>
    <intervention_summary>Other: IBD multidisciplinary team model including IBD nurse</intervention_summary>
    <last_changed>June 20, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>700</order>
    <score>0.5649</score>
    <nct_id>NCT02269358</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02269358</url>
    <title>Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: METHOTREXATE</intervention_summary>
    <last_changed>August 10, 2016</last_changed>
  </clinical_study>
</search_results>
